INVO Fertility Inc. has released its unaudited pro forma financial statements reflecting the divestiture of its majority holdings in NAYA Therapeutics Inc. $(NTI.AU)$. The NTI Divestiture, consummated on June 2, 2025, involved the redemption of Series C-1 Non-Voting Convertible Preferred Stock in exchange for shares of Class A Common Stock of NTI. The pro forma financials, which include a consolidated balance sheet as of March 31, 2025, and statements of operations for the three months ended March 31, 2025, and the year ended December 31, 2024, provide insights into INVO's financial condition post-divestiture. The statements are intended for informational purposes and should be read alongside INVO's historical financial reports.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。